Department of Pathology, University of California, San Diego / 9500 Gilman Dr. La Jolla, CA 92093, U.S.A.;.
Department of Neurosciences, University of California, San Diego / 9500 Gilman Dr. La Jolla, CA 92093, U.S.A.
Int J Mol Sci. 2009 Mar;10(3):1045-1063. doi: 10.3390/ijms10031045. Epub 2009 Mar 11.
The cognitive deficits in patients with HIV profoundly affect the quality of life of people living with this disease and have often been linked to the neuro-inflammatory condition known as HIV encephalitis (HIVE). With the advent of more effective anti-retroviral therapies, HIVE has shifted from a sub-acute to a chronic condition. The neurodegenerative process in patients with HIVE is characterized by synaptic and dendritic damage to pyramidal neurons, loss of calbindin-immunoreactive interneurons and myelin loss. The mechanisms leading to neurodegeneration in HIVE might involve a variety of pathways, and several lines of investigation have found that interference with signaling factors mediating neuroprotection might play an important role. These signaling pathways include, among others, the GSK3beta, CDK5, ERK, Pyk2, p38 and JNK cascades. Of these, GSK3beta has been a primary focus of many previous studies showing that in infected patients, HIV proteins and neurotoxins secreted by immune-activated cells in the brain abnormally activate this pathway, which is otherwise regulated by growth factors such as FGF. Interestingly, modulation of the GSK3beta signaling pathway by FGF1 or GSK3beta inhibitors (lithium, valproic acid) is protective against HIV neurotoxicity, and several pilot clinical trials have demonstrated cognitive improvements in HIV patients treated with GSK3beta inhibitors. In addition to the GSK3beta pathway, the CDK5 pathway has recently been implicated as a mediator of neurotoxicity in HIV, and HIV proteins might activate this pathway and subsequently disrupt the diverse processes that CDK5 regulates, including synapse formation and plasticity and neurogenesis. Taken together, the GSK3beta and CDK5 signaling pathways are important regulators of neurotoxicity in HIV, and modulation of these factors might have therapeutic potential in the treatment of patients suffering from HIVE. In this context, the subsequent sections will focus on reviewing the involvement of the GSK3beta and CDK5 pathways in neurodegeneration in HIV.
HIV 感染者的认知缺陷严重影响了他们的生活质量,并且常常与被称为 HIV 脑炎(HIVE)的神经炎症状态有关。随着更有效的抗逆转录病毒疗法的出现,HIVE 已经从亚急性转变为慢性疾病。HIVE 患者的神经退行性过程的特征是锥体神经元的突触和树突损伤、钙结合蛋白免疫反应性中间神经元的丧失和髓鞘丢失。HIVE 中神经退行性变的机制可能涉及多种途径,并且有几条研究线索发现,干扰介导神经保护的信号因子可能发挥重要作用。这些信号通路包括 GSK3β、CDK5、ERK、Pyk2、p38 和 JNK 级联等。在这些通路中,GSK3β 一直是许多先前研究的重点,这些研究表明,在感染患者中,HIV 蛋白和免疫激活细胞在大脑中分泌的神经毒素异常激活了该通路,而该通路通常受 FGF 等生长因子的调节。有趣的是,通过 FGF1 或 GSK3β 抑制剂(锂、丙戊酸)调节 GSK3β 信号通路对 HIV 神经毒性具有保护作用,几项初步临床试验表明,用 GSK3β 抑制剂治疗的 HIV 患者认知能力得到了改善。除了 GSK3β 通路外,CDK5 通路最近也被认为是 HIV 神经毒性的介导物,HIV 蛋白可能激活该通路,随后破坏 CDK5 调节的各种过程,包括突触形成和可塑性以及神经发生。总之,GSK3β 和 CDK5 信号通路是 HIV 神经毒性的重要调节剂,调节这些因素可能具有治疗 HIVE 患者的潜在治疗作用。在这方面,接下来的部分将重点回顾 GSK3β 和 CDK5 通路在 HIV 神经退行性变中的作用。